{"word_count": 264, "character_count": 1948}
Project acronym: NANOSARC-TTopics: cancer, liposarcoma, genotherapy, nanovectorDisciplinary fields: chemistry, physical chemistry, biology, pharmacology, medicineSummary: The project is aiming to the improvement of the therapy against dedifferentiated liposarcoma. Efficiency, patient comfort and controlled costs are major challenges in the fight against cancer. The development of a non-invasive therapy would be advantageous. The &#160;goal is to develop an efficient genotherapy, with the use of antisense oligonucleotides ASO combined to nanovector in order to protect them and dramatically increase their effective delivery into the cancer cells. In association to radiotherapy, taking advantage of the expected radiosensitizer effect of the nanoparticles, this treatment would enhance the efficiency of the surgical therapy, and even prevent from it, at early stage. The project is based on the use of new small hybrid nanoparticles. The main focus is on the “molecular” scale control of the approach, including high purification and characterization of the nanovector, as well as multi-scale assays and imaging methods. The clue is also the interdisciplinaity, to select the best leads and to control the key factors of the whole process, including chemistry, physical chemistry, biology, phamacology and oncology, from the lab scale up to in-vivo assays. Imaging of the injected systems, in-vitro and in-vivo is a critical clue for the control and the optimization of our approach. This integrated process is offering the unique opportunity to share the tools and technics, to combine the experimental and modelling works, to enhance a multi-scale view of faster and with better resultProject Interlocutor:&#160;Frédéric Dallemer, Laboratoire MADIREL (UMR 7246)Project duration&#160;:&#160;03/01/2018&#160;-&#160;02/28/2021Call for application:  Interdisciplinarité 2016Photography credits: Photography by Hans Reniers on Unsplash, License